diclofenac potassium + nimesulide

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Upper Respiratory Tract Infections

Conditions

Upper Respiratory Tract Infections

Trial Timeline

Apr 1, 2011 → —

About diclofenac potassium + nimesulide

diclofenac potassium + nimesulide is a approved stage product being developed by Novartis for Upper Respiratory Tract Infections. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01257126. Target conditions include Upper Respiratory Tract Infections.

What happened to similar drugs?

5 of 14 similar drugs in Upper Respiratory Tract Infections were approved

Approved (5) Terminated (0) Active (9)
Remimazolam TosilateJiangsu Hengrui MedicineApproved
BOTOXAbbVieApproved
Montelukast + PlaceboMerckApproved
Diclofenac gelNovartisApproved
AboBoNT-A + OnaBoNT-AIpsenApproved
🔄Muntelukast + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01257126ApprovedWithdrawn

Competing Products

20 competing products in Upper Respiratory Tract Infections

See all competitors